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The proximal region of chromosome 15 is one of the genomic hotspots for copy number variants (CNVs). Among the
rearrangements observed in this region, CNVs from the interval between the common breakpoints 1 and 2 (BP1 and BP2)
have been reported cosegregating with autism spectrum disorder (ASD). Although evidence supporting an association
between BP1-BP2 CNVs and autism accumulates, the magnitude of the effect of BP1-BP2 CNVs remains elusive, posing
a great challenge to recurrence-risk counseling. To gain further insight into their pathogenicity for ASD, we estimated the
penetrance of the BP1-BP2 CNVs for ASD as well as their effects on ASD-related phenotypes in a well-characterized ASD
sample (n = 2525 families). Transmission disequilibrium test revealed significant preferential transmission only for the
duplicated chromosome in probands (20T:9NT). The penetrance of the BP1-BP2 CNVs for ASD was low, conferring
additional risks of 0.3% (deletion) and 0.8% (duplication). Stepwise regression analyses suggest a greater effect of the
CNVs on ASD-related phenotype in males and when maternally inherited. Taken together, the results are consistent with
BP1-BP2 CNVs as risk factors for autism. However, their effect is modest, more akin to that seen for common variants.
To be consistent with the current American College of Medical Genetics guidelines for interpretation of postnatal CNV,
the BP1-BP2 deletion and duplication CNVs would probably best be classified as variants of uncertain significance
(VOUS): they appear to have an impact on risk, but one so modest that these CNVs do not merit pathogenic status.
Autism Res 2014, 7: 355–362. © 2014 International Society for Autism Research, Wiley Periodicals, Inc.
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Introduction
While converging results underscore the importance of
rare de novo events of large effect on autism spectrum
disorder (ASD) [Pinto et al., 2010; Sanders et al., 2011], it
has proven challenging to estimate the contribution of
inherited copy number variants (CNVs) [Bucan et al.,
2009; Girirajan, Johnson et al., 2013; Krumm et al., 2013;
Morrow et al., 2008; Pinto et al., 2010; Sanders et al.,
2011]. There is no doubt, however, that some rare inher-
ited CNVs substantially increase risk, e.g. deletion or
duplication of loci affected by recurrent de novo CNVs,
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notably 16p11.2 [Sanders et al., 2011; Weiss et al., 2008].
Still, at the population level, the contribution to risk from
individual inherited variants of large effect should be
small because the individual variants are subject to
natural selection [Devlin & Scherer, 2012], while rare
inherited variants that modestly increase risk could play a
substantial role in the genetic architecture of the disorder.
The 15q11.2-q13 region harbors five common break-
points (BP1, BP2, BP3, BP4, and BP5), each breakpoint
corresponding to a complex set of segmental duplications
[Christian, Fantes, Mewborn, Huang, & Ledbetter, 1999].
While the large effect of BP1-BP3, BP2-BP3, and BP4-BP5
CNVs on neurodevelopment has been well established
[Cook et al., 1997; Girirajan, Dennis et al., 2013;
Moreno-De-Luca et al., 2012; Shen et al., 2010], the
picture is considerably less clear for the effects of BP1-BP2
CNVs. The BP1-BP2 genomic interval within band
15q11.2 (henceforth “BP1-BP2” and “15q11.2” are used
synonymously.) encompasses four genes not known to be
imprinted: NIPA1, NIPA2, CYFIP1, and TUBGCP5. Inter-
estingly, while the BP2-BP3 region is considered the criti-
cal region for Prader–Willi syndrome (PWS) and
Angelman syndrome (AS), some have reported a correla-
tion between the type of deletion (i.e., BP1-BP3 deletion
vs. BP2-BP3 deletion) and the severity of the phenotype
[Butler, Bittel, Kibiryeva, Talebizadeh, & Thompson,
2004; Hartley, Maclean, Butler, Zarcone, & Thompson,
2005; Sahoo et al., 2007]. Moreover, data accumulate to
support the role of BP1-BP2 deletion, and to a lesser
extent duplication, as risk factors for several neuro-
developmental disorders, such as schizophrenia, develop-
mental delay, intellectual disability with or without
dysmorphism, epilepsy, and ASD [Abdelmoity et al.,
2012; Burnside et al., 2011; de Kovel et al., 2010;
Doornbos et al., 2009; Murthy et al., 2007; Sempere Perez
et al., 2011; van der Zwaag et al., 2010; von der Lippe,
Rustad, Heimdal, & Rodningen, 2011; Vassos et al., 2010].
The magnitude of their effect, however, remains
uncertain.
A primary concern for genetic counseling is how
much a BP1-BP2 CNV increases the risk of autism. Our
goal in this research is to provide as much information
as possible in this context. Estimating the penetrance of
the CNV for autism is a key step in that process. Pen-
etrance of BP1-BP2 CNVs is likely to be low because the
vast majority of BP1-BP2 CNVs identified in clinical
cohorts are inherited from healthy parents, and BP1-BP2
CNVs have been identified in control subjects. However,
penetrance estimates vary widely across studies for the
deletion (from 0.10 to 0.83) [Cooper et al., 2011;
Rosenfeld, Coe, Eichler, Cuckle, & Shaffer, 2013] and are
lacking for the duplication. Moreover, the contribution
of BP1-BP2 CNVs to ASD risk, as opposed to develop-
mental disorders more broadly, has never been exam-
ined separately.
Characterization of parent and sibling carriers can also
inform our understanding of the nature of risk and has
proven fruitful in several instances [Girirajan & Eichler,
2010; Zufferey et al., 2012]. Given the great phenotypic
heterogeneity of ASD, which is thought to reflect the
extensive complexity of the architecture of genetic risk
for autism, studying subtle autistic symptoms in relatives
can disentangle the effect of variants on phenotype. Fur-
thermore, it is important to examine the relationship of
CNV and phenotype in probands, such as sex-specific
expression and the effect of parent of origin. To gain
insight into the pathogenicity of the BP1-BP2 CNVs, we
study a well-characterized ASD family sample (n = 2525
families) from the Simons Foundation Autism Research
Initiative (SFARI). To our knowledge, this is the first
attempt to examine the pathogenicity of the BP1-BP2
CNVs specifically for ASD.
Methods
ASD Families
Included were a total of 2525 ASD families with both
phenotype and genotype data available. These consist of
2482 families from the Simons Simplex Collection (SSC)
(version 14.1), 31 families from the Simons Ancillary
Collection (SAC), and 12 monozygotic twin families from
the Simons Twin Collection (STC). The main properties
of the families in the SSC have been described by
Fischbach and Lord [Fischbach & Lord, 2010]. Additional
information on the SAC and STC families is included in
the Supporting Information. The ASD sample consists of
2525 fathers, 2525 mothers, 2036 designated siblings (s1),
and 2525 designated probands (p1). All individuals in
this sample were older than 4 years. Further information
regarding inclusion/exclusion criteria for SSC, SAC, and
STC, as well as the complete list of instruments used to
assess the phenotype of the families, are available on the
SFARI website (https://sfari.org/).
Phenotype Measures
For parents, the average score of the Broad Autism Pheno-
type Questionnaire (BAPQ) [Hurley, Losh, Parlier, Reznick,
& Piven, 2007] and the total raw score of the Social
Responsiveness Scale (SRS) [Constantino & Gruber, 2005],
adult version (SRS-A) were included in the analysis. For
siblings, the total T score of SRS-Parent version (SRS-P) was
analyzed. The SRS-P score was not analyzed in the pro-
bands because the distribution of the scores showed a
major ceiling effect in probands. Composite score of the
Vineland Adaptive Behavior Scale-2nd edition (VABS-II)
[Sparrow, Cicchetti, & Bella, 2005] was analyzed in both
probands and siblings, separately. For probands only, the
effects of the CNVs on Calibrated Severity Scales (CSS)
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[Gotham, Pickles, & Lord, 2009; Hus, Gotham, & Lord,
2012] of Social affect (SA-CSS) and restricted repetitive
behavior (RRB-CSS) from the Autism Diagnostic Observa-
tion Schedule-WPS edition [Lord, Rutter, DiLavore, & Risi,
2006], and intellectual quotient (IQ) consisting of full
scale IQ, verbal IQ (VIQ), andnonverbal IQ,weremodeled.
IQ scores were derived from one or more of the following
instruments: Differential Ability Scales, 2nd edition
[Elliott, 2007], Wechsler Intelligence Scale for Children,
4th edition [Wechsler, 2004], Mullen Scales of Early Learn-
ing [Mullen, 1995], or the Raven’s standard progressive
matrices [Raven, 1981]. When children had the Raven’s,
VIQ was estimated from the Peabody Picture Vocabulary
Test-4th edition [Dunn & Dunn, 2007].
Microarray Analyses
The ASD families were genotyped on the Illumina
Infinium®1Mv1 (338 families), Infinium®1Mv3 Duo
(1191 families), or the HumanOmni2.5–8 (996 families)
microarrays (Illumina Inc, San Diego, CA, USA). All three
microarray types had over 180 probes within the BP1-BP2
region. CNV prediction was performed by PennCNV (PN)
[Wang et al., 2007], QuantiSNP (QT) [Colella et al., 2007],
and Gnosis [Sanders et al., 2011], using CNVision
[Sanders et al., 2011]. Detailed CNV detection protocol
was described in [Sanders et al., 2011]. Sample identity
within the family, including correct assignment of pater-
nity and maternity, was confirmed using genetically
inferred identity by descent for all study participants,
including the de novo deletion of BP1-BP2 in a proband.
Statistical Analysis
The distributions of SRS scores (SRS-A and SRS-P) in unaf-
fected relatives were not symmetric (Fig. S1). Because
extreme observations (out in the tail) can act as “influ-
ence points” for regression effects, we analyzed all data
using the square root of SRS scores. The effects of BP1-BP2
CNVs in parents on ASD-related phenotypes were exam-
ined using generalized estimating equations (GEE) to take
into account the correlation between the mother and
father SRS scores and the mother and father BAPQ scores.
Linear regression was used to explore the results obtained
with GEE further by analyzing the mothers and fathers
separately. All analyses were done using R (http://cran.r-
project.org). GEE was implemented using the gee
package, with the identity variable being family; the cor-
relation among family members was defined as fixed for
the correlation between parents’ scores (0.34 for SRS and
0.11 for BAPQ).
All the models initially included sex and age as
covariates, as well as sex × CNV interaction. Covariates
were dropped when they were nonsignificant predictors,
thereby identifying the most parsimonious model. For
modeling the relationship between BP1-BP2 CNV and
phenotype, we made the a priori assumption that both
the deletion and duplication had a similar effect on phe-
notype: the relatively small number of both deletions and
duplications would not permit distinction of subtle dif-
ferences, even if they exist.
Transmission Disequilibrium Test and
Penetrance Calculations
The transmission equilibrium of inherited CNVs in our
ASD family sample was examined to further evaluate
pathogenicity of the BP1-BP2 CNVs, using chi statistics.
Penetrance estimate was calculated as a conditional
probability: P(D|G) = P(G|D) × P(D)/[P(G|D) × P(D)
+ P(G|∼D) × (1-P(D))] [Vassos et al., 2010], in which P is
probability, D means the subject is diagnosed with ASD,
∼D means the subject is unaffected, G encodes carrier
status for BP1-BP2 CNV, and P(D|G) is read as the prob-
ability of being diagnosed with ASD given the subject
carries a BP1-BP2 CNV. The subtlety here is that this
cohort was ascertained for affected probands, and thus to
solve for the penetrance P(D|G) we must reverse the
conditional (e.g., [P(G|D)) and use an estimate of the
prevalence of ASD, P(D), which we take to be equal to
0.01. The penetrance estimate was performed separately
for deletion and duplication because published results
from other cohorts suggest they differ somewhat in their
penetrance for other developmental and neuropsychiat-
ric outcomes [Cooper et al., 2011; Kirov et al., 2013]. We
also estimated the penetrance for the deletion and dupli-
cation combined.
Results
Estimate of Frequency and Penetrance of BP1-BP2 CNVs
Eighty-nine subjects in 47 families carried a CNV involv-
ing the BP1-BP2 region of chromosome 15. Among those,
four families were excluded from all analyses due to the
presence of a larger 15q11.2–13 CNV involving the
PWS/AS region (Table S1); all four were de novo CNVs in
probands. One father–proband pair carried a BP1-BP2
duplication involving only two genes (TUBGCP5 and
CYFIP1); this pair was included in the analyses. In the
remaining 85 subjects in 43 families, the BP1-BP2 dele-
tion was observed in 6/2525 fathers, 8/2525 mothers,
5/2036 siblings, and 8/2521 probands, whereas BP1-BP2
duplication was observed in 16/2525 fathers, 13/2525
mothers, 9/2036 siblings, and 20/2521 probands. So the
rates of deletion (duplication) were 0.28% (0.57%) in
parents, 0.25% (0.44%) in unaffected siblings (s1), and
0.32% (0.79%) in probands, respectively (Table 1).
Only one CNV, a deletion, was de novo and it was
transmitted by the father. Neither the frequency of the
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deletion nor the frequency of the duplication differed
significantly between ASD probands and siblings
(P = 0.86 and P = 0.19, respectively). The frequency of the
deletion was comparable to published rates in controls
(0.18–0.38%) [Cooper et al., 2011; Rosenfeld et al., 2013;
Stefansson et al., 2008] and somewhat lower than in indi-
viduals with schizophrenia (0.59% [Kirov et al., 2013] to
0.62% [Vassos et al., 2010]), or in subjects with develop-
mental delay (0.60% [Cooper et al., 2011] to 0.81%
[Rosenfeld et al., 2013]). The frequency of the duplication
in ASD probands was higher than the previously pub-
lished rates in both cases (0.41% [Cooper et al., 2011])
and controls (0.34% [Stefansson et al., 2008] to 0.43%
[Cooper et al., 2011]). No parent-of-origin-specific distor-
tion of parental transmission was observed in this sample
(Table S2).
The estimate of penetrance was 0.013 for the deletion
and 0.018 for the duplication (0.016 for either), given a
prevalence of 0.01 for ASD [Centers for Disease Control,
CDC, 2006, 2012], which means that the presence of the
BP1-BP2 deletion/duplication would increase the risk of
having autism by about three in a thousand for the dele-
tion and eight in a thousand for the duplication.
However, the confidence interval (CI) of the odds ratio
(OR) is quite large (deletion: OR = 1.3 CI 95% = [0.42–
3.96]; duplication OR = 1.8, CI 95% = [0.82–3.97]).
Transmission Analysis of BP1-BP2 CNVs
There was no preferential transmission of the deletion,
either in probands or siblings in this sample, whereas the
duplication was preferentially transmitted from parents
to probands (20T vs. 9NT, X2 = 4.2, one-tailed P = 0.041)
but not to unaffected siblings (Table S3 and Fig. S2). Inter-
estingly, preferential transmission of duplication was
most evident in trio families (10T vs. 0NT) vs. quartet
families (10T vs. 9NT). We explored further the transmis-
sion results for “stoppage effect (stop having children
after the proband)” in relation to birth orders of the
probands. We did not observe any meaningful pattern
between trio and quartet families. Transmission to sib-
lings and probands appears similar between fathers and
mothers.
Effects of BP1-BP2 CNVs on Autism-Related Symptoms
in Relatives
In parents, the model including both sex and sex × CNV
interaction revealed nominally significant CNV effect on
SRS score in parents (Table 2). When the model was sim-
plified, however, by dropping age (nonsignificant effect)
and sex × CNV interaction (close to significance), the
CNV effect on SRS score became not significant. Because
these results suggest that there may be a modest differ-
ence between mothers and fathers in the effect of the
CNV, data from mothers and data from fathers were ana-
lyzed separately. The results (Table S4) were consistent
with a greater effect of the CNV on SRS scores in fathers
than mothers. GEE analysis for BAPQ score was not sig-
nificant with or without sex and age included in the
model (Table 2).
In siblings (Table S4), a CNV effect on SRS score was not
observed either overall or in male siblings only (estimate
−0.08946, P value 0.67); however, there was a significant
effect of “parent-of-origin” (PoO) on SRS score (Table S4),
specifically CNVs from mothers had a greater impact
than those from fathers. Thus, there appeared to be
modest heterogeneity by PoO, but it is important to also
note the small sample size of 13 siblings (one did not
have SRS data). Last, while the analysis of the effect of the
CNV on composite score of VABS in siblings did not
reveal a significant CNV effect, the results of the model
including PoO, sex, and an interaction between PoO and
sex suggested a trend toward a greater effect in males who
received the CNV from their mother.
Table 1. BP1-BP2 CNV Frequency in 2525 ASD Families
15q11.2 CNV Father Mother s1 p1
BP1-BP2 deletion 6 8 5 8
BP1-BP2 duplication 16 13 9 20
No CNV 2503 2504 2022 2493
CNV overlapping the PWS/AS CR 0 0 0 4
Sum 2525 2525 2036 2525
ASD, autism spectrum disorder; CNV, copy number variant; PWS/AS CR,
Prader-Willi/Angelman Syndrome Critical Region (BP2-BP3); s1, desig-
nated sibling; p1, designated proband.
Table 2. Effect of CNV on SRS (Square Root) and BAPQ Scores in Parents Using Generalized Estimating Equations
Clinical Measure Predictors Estimate Naïve SE Naïve z Robust SE Robust z P value
SRS CNV 1.04661980 0.41466441 2.524016 0.53327662 1.962621 0.0497
Sex 0.05556904 0.05480882 1.013870 0.05473152 1.015302 0.31
Sex × CNV −1.09070467 0.59330134 −1.838365 0.65829129 −1.656872 0.0975
BAPQ CNV 0.1122471 0.09024223 1.243842 0.09343174 1.20138 0.23
sex −0.2915663 0.01665541 −17.505799 0.01665045 −17.51102 1.18x10−68
SRS, Social Responsiveness Scale; BAPQ, Broad Autism Phenotype Questionnaire; sex × CNV, interaction between sex and CNV; CNV, copy number variant.
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The Effects of BP1-BP2 CNVs in Probands
Before analyses, two probands were excluded from the
phenotype/genotype analyses because they carried a large
de novo CNV (3.5 Mb and 5.4 Mb respectively) in
another chromosome (Table S1). Performing the same
stepwise analyses described earlier, neither the analysis of
the effect of CNV nor the analysis of PoO supported a
large effect of the CNV on any of the analyzed pheno-
types (Table S5), and there was no consistency between
the results of the different models.
Discussion
ASD is a group of heterogeneous neurodevelopmental
disorders causing significant social, communication, and
behavioral deficits and challenges [APA, 2000]. While
genome-wide genotyping and sequencing are beginning
to elucidate the complex architecture of autism risk, the
contribution of inherited rare variation to genetic risk for
autism remains elusive [Bucan et al., 2009; Girirajan,
Johnson et al., 2013; Krumm et al., 2013; Morrow et al.,
2008; Pinto et al., 2010; Sanders et al., 2011, 2012].
Although this contribution is likely to be low in terms of
proportion of phenotype explained in a sample (i.e., heri-
tability related to rare inherited variation), it is an impor-
tant issue at the individual level because of the
consequences for genetic counseling. Moreover, the dis-
covery of some inherited CNVs occurring at loci affected
by de novo CNVs shows that some rare inherited varia-
tion carries risk for ASD. To gain further insight into the
pathogenicity of the BP1-BP2 CNVs, which have been
proposed as risk factors for ASD, we have estimated the
penetrance of the CNV and effects on ASD phenotype in
a well-defined ASD family sample.
Intriguingly, the results obtained in this sample are
different than the results from previous studies on broader
neurodevelopmental phenotypes [Cooper et al., 2011].
Indeed, there was no evidence of association between the
deletion and ASD in this sample, whereas a significant
over-transmission of the duplication to probands was
observed. Moreover, the estimated penetrance was lower
for the deletion than for the duplication (0.013 vs. 0.018).
This could be the consequence of an ascertainment bias.
For this sample, parents were selected so that they did not
present with even a mild autism phenotype, and they
would thus be different from the unscreened parental
population. A relevant observation is that the frequency of
BP1-BP2 deletion in both unaffected relatives and pro-
bands was similar to published rates in controls [Cooper
et al., 2011; Rosenfeld et al., 2013; Stefansson et al., 2008].
While it is possible that differences in CNV detection
confound interpretation of these data, another plausible
explanation for these differences is that the recruitment
modalities of the SFARI lead to the selection of families less
likely to carry rare, inherited ASD risk variation, such as
BP1-BP2CNVs. Certainly, this was the purpose of the strict
family assessment of the SFARI, and its impact has been
documented for common variants affecting risk for ASD
[Klei et al., 2012].While in this study the penetrance of the
duplication was estimated to be slightly higher than the
penetrance of the deletion, this could also be a result of
ascertainment bias: families with the duplication being
less likely to have been excluded because the duplication
has smaller phenotypic effect, while the smaller sample
size of parents carrying deletions translates to greater
variance in transmission than that for duplications. The
sole BP1-BP2 de novo event, a deletion, lends some cre-
dence to this possibility. Thus, it is possible, given these
results, that the impact of BP1-BP2 on risk is somewhat
underestimated by our study. Nonetheless, there can be no
doubt that its impact is modest and its penetrance is low.
All other results are consistent with a very modest
effect. Interestingly, the results of the regression analysis
of the effect of the CNVs on SRS scores suggested that
males might be more sensitive to the effect of the CNV,
with a greater effect of CNVs in fathers than in mothers.
Still, there is no effect of presence of the CNV on the score
for the BAPQ for any model. It is tempting to say that
these results show that the impact of the CNV is princi-
pally on sociability unrelated to broader autism pheno-
types, but that interpretation must be tempered by the
ascertainment used to recruit parents for the study,
namely that they show few if any traits of the broader
autism phenotype. This confounding limits our ability to
interpret negative findings, but bolsters our confidence in
positive results, which move contrary to expectations
based on the ascertainment of parents for this study.
When we evaluated the effects of the BP1-BP2 CNVs on
the severity of autism phenotype in probands, we did not
observe any effect of the CNV in a positive or negative
direction. This is consistent with the low penetrance and
low impact on risk, suggesting this CNV and other risk
factors, perhaps many, are required for a carrier to be
diagnosed with ASD. The results yield a glimpse of the
great challenge of identifying rare inherited variants that
increase risk for autism.
To our knowledge, this is the first systematic study to
investigate the effect of the BP1-BP2 CNVs on ASD risk.
The results suggest that BP1-BP2 CNVs confer very little
additional risk for ASD. One intriguing observation is
that the effect of maternally inherited CNVs effect could
be slightly higher than attributable to paternally inher-
ited CNVs. However, these results should be considered as
exploratory, and larger samples will be required to under-
stand if this effect is confirmed or simply a stochastic
effect due to small sample size and multiple testing. The
main limitation of this study is the relatively small
sample size of carriers, consistent with the rarity of the
BP1-BP2 CNVs in the population in general. To replicate
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our results on penetrance with good power (80%, with
α = 0.05), for example, a very large sample size will be
required (20027 probands and controls for the deletion,
3466 probands controls for the duplication). However, a
strength of this study is that the family-based analyses
avoid population structure bias, which is likely to be
important in studies of rare variants [Liu, Fast,
Zawistowski, & Tintle, 2013]. In any case, the results of
this study strongly suggest that the effect on ASD risk is
small. Following the current American College of Medical
Genetics guidelines for interpretation of postnatal CNV
[Kearney, Thorland, Brown, Quintero-Rivera, & South,
2011], these CNVs remain classified as variants of
unknown significance (VOUS).
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